GLP 1 Research and Regulatory Insights Webinar for the Nutra Industry
SGS, the world’s leading testing, inspection and certification company, is delighted to present a complimentary webinar, ‘The GLP-1 craze decoded: current research and regulatory insights for the nutra industry,’ on February 27, 2025.
Hormone-focused solutions for appetite modulation and weight management, such as GLP-1, are attracting significant attention within the nutraceutical industry. As market opportunities expand, regulatory scrutiny around ingredients and applications is increasing to ensure consumer safety. Companies must carefully balance innovation with compliance to succeed.
In this webinar, presenters Dr. Stephanie-Anne Girard and Erin Taraborelli will examine how GLP-1 receptor agonists work and how the nutraceutical industry is responding. They will also explore current research finding from the US and Canada on safety and efficacy and discuss their impact on brands.
Additionally, the webinar will provide guidance on strategic pathways for market entry, offering expert insights to help brands navigate the evolving regulatory landscape.
This webinar is ideal for finished product brands and ingredient manufacturers in the nutraceutical industry.
About SGS
SGS is the world’s leading Testing, Inspection and Certification company. We operate a network of over 2,500 laboratories and business facilities across 115 countries, supported by a team of 99,500 dedicated professionals. With over 145 years of service excellence, we combine the precision and accuracy that define Swiss companies to help organizations achieve the highest standards of quality, compliance and sustainability.
Our brand promise – when you need to be sure – underscores our commitment to trust, integrity and reliability, enabling businesses to thrive with confidence. We proudly deliver our expert services through the SGS name and trusted specialized brands, including Brightsight, Bluesign, Maine Pointe and Nutrasource.
SGS is publicly traded on the SIX Swiss Exchange under the ticker symbol SGSN (ISIN CH0002497458, Reuters SGSN.S, Bloomberg SGSN:SW).